Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)

First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials